Treatment of invasive candidiasis: between guidelines and daily clinical practice

References

• Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23(4):317-22
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3(11):685-702
   PubMed Web of Science ®Google Scholar
• Bassetti M, Merelli M, Righi E, et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 2013;51(12):4167-72
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006;6:21
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Moet GJ, Messer SA, et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011;49(1):396-9
   PubMed Web of Science ®Google Scholar
• Bow EJ, Evans G, Fuller J, et al. Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol 2010;21(4):e122-50
   PubMed Web of Science ®Google Scholar
• Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002;50(4):243-60
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
   PubMed Web of Science ®Google Scholar
• Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009;48(12):1695-703
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49(9):3640-5
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007;45(6):1843-50
   PubMed Web of Science ®Google Scholar
• Choi HW, Shin JH, Jung SI, et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 2007;51(4):1520-3
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Fiori B, Trecarichi EM, et al. Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One 2012;7(3):e33705
   PubMedGoogle Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18(Suppl 7):19-37
   PubMed Web of Science ®Google Scholar
• Schuster MG, Edwards JEJr, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008;149(2):83-90
   PubMed Web of Science ®Google Scholar
• León C, Ruiz-Santana S, Saavedra P, Cava Study Group. Usefulness of the ‘Candida score’ for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009;37(5):1624-33
   PubMed Web of Science ®Google Scholar
• Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med 2014;40(10):1429-48
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007;26(4):271-6
   PubMed Web of Science ®Google Scholar
• Tascini C, Sbrana F, Cardinali G, et al. Arterial blood culture to hasten the diagnosis of candidemia in critically ill patients. Intensive Care Med 2014;40(7):1059-60
   PubMed Web of Science ®Google Scholar
• Mikulska M, Calandra T, Sanguinetti M, Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010;14(6):R222
   PubMed Web of Science ®Google Scholar
• Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 2012;55(4):521-6
   PubMed Web of Science ®Google Scholar
• Ahmad S, Khan Z. Invasive candidiasis: a review of nonculture-based laboratory diagnostic methods. Indian J Med Microbiol 2012;30(3):264-9
   PubMed Web of Science ®Google Scholar
• Wagner C, Graninger W, Presterl E, Joukhadar C. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006;78(4):161-77; Epub 2006 Oct 17
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82
   PubMed Web of Science ®Google Scholar
• Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011;55(2):532-8
   PubMed Web of Science ®Google Scholar
• Blanchard E, Lortholary O, Boukris-Sitbon K, et al. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother 2011;55(11):5358-61
   PubMed Web of Science ®Google Scholar
• Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013;56(12):1724-32
   PubMed Web of Science ®Google Scholar
• Neoh CF, Liew D, Slavin M, et al. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. J Antimicrob Chemother 2011;66(8):1906-15
   PubMed Web of Science ®Google Scholar
• Grau S, Salavert M, Carlos Pozo Laderas J, et al. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain. J Mycol Med 2013;23(3):155-63
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care 2009;13(3):R94
   PubMed Web of Science ®Google Scholar
• Golan Y, Wolf MP, Pauker SG, et al. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med 2005;143(12):857-69
   PubMed Web of Science ®Google Scholar
• Neoh CF, Liew D, Slavin MA, et al. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis. Intern Med J 2013;43(6):668-77
   PubMed Web of Science ®Google Scholar
• Turner SJ, Senol E, Kara A, et al. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey. Int J Antimicrob Agents 2013;42(3):276-80
   PubMed Web of Science ®Google Scholar
• Wingard JR, Wood CA, Sullivan E, et al. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther 2005;27(6):960-9
   PubMed Web of Science ®Google Scholar
• Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008;24(6):1743-53
   PubMed Web of Science ®Google Scholar
• Masterton RG, Casamayor M, Musingarimi P, et al. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections. J Med Econ 2013;16(11):1344-56
   PubMedGoogle Scholar
• Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res 2011;16(4):180-6
   PubMed Web of Science ®Google Scholar
• Ruhnke M. Antifungal stewardship in invasive Candida infections. Clin Microbiol Infect 2014;20(Suppl 6):11-18
   PubMed Web of Science ®Google Scholar